Missense mutations of the lamin A/C gene, LMNA, have been recently identified in Dunnigan-type familial partial lipodystrophy (FPLD), which belongs to a heterogeneous group of rare disorders affecting adipose tissue distribution and metabolism. In this study, we sequenced the LMNA coding region from patients presenting with FPLD or other forms of lipodystrophy. We identified two heterozygous mutations in exon 8, R482W and R482Q, in FPLD patients (six families and one individual) with various clinical presentations. In addition, we found a novel heterozygous mutation (R584H) in exon 11, encoding specifically the lamin A isoform, in a patient with typical FPLD. Clinical and biochemical investigations in FPLD patients revealed that the expression and the severity of the phenotype were markedly dependent on sex, with female patients being more markedly affected. In subjects with generalized lipoatrophy, either congenital (13 case subjects) or acquired (14 case subjects), or Barraquer-Simon syndrome (2 case subjects), the entire LMNA coding sequence was normal. Although FPLD mutations are predominantly localized in exon 8 of LMNA, the finding of a novel mutation at codon 584, together with the R582H heterozygous substitution recently described, confirms that the C-terminal region specific to the lamin A isoform is a second susceptibility region for mutations in FPLD.
L
ipodystrophies represent a heterogeneous group of diseases characterized by alterations in body fat distribution and, in most cases, insulin resistance. The other cardinal signs are acanthosis nigricans, hyperandrogenism in females, muscular hypertrophy, hepatomegaly, altered glucose tolerance, and hypertriglyceridemia (1) . Among them, the familial partial lipodystrophy of the Dunnigan type (FPLD), dominantly inherited, is characterized by a lack of adipose tissue in the limbs, buttocks, and trunk with fat accumulation in the neck and face, and results from heterozygous missense mutations of LMNA (2) (3) (4) (5) . Lamin A and C, encoded by this gene, are ubiquitous structural proteins that polymerize in the nuclear lamina, a meshwork underlying the inner nuclear membrane, in which they interact with integral proteins and chromatin (6) .
In the present study, we searched for mutations in LMNA in patients affected with FPLD or other lipodystrophies and analyzed the different clinical presentations.
Concerning FPLD, we sequenced the coding region of LMNA in the probands from six families and two individuals. Previous haplotype analysis at the FPLD locus (chromosome 1q) confirmed that these Caucasian families were not related (data not shown). A heterozygous CGG→TGG transition at codon 482 (exon 8), leading to an arginine to tryptophane substitution (R482W) was found in probands from families DE, DR, G, K, H, and P. At the same codon, patient J.M. displayed a heterozygous CGG→CAG transition, which predicts an arginine to glutamine substitution (R482Q). These mutations have been previously reported in FPLD (2) (3) (4) (5) .
In patient PI, we found a heterozygous CGC→CAC transition at codon 584 (exon 11), leading to an arginine to histidine substitution (R584H). This DNA variation, which has not been previously reported, was absent in 100 unrelated control subjects screened using a Dra III restriction polymor-phism (see RESEARCH DESIGN AND METHODS), therefore representing a new LMNA mutation.
The dominant transmission of FPLD was evident in each of the families (Fig. 1 ) and was considered likely in individuals J.M. and P.I., because lipodystrophy was observed in their mothers, one of whom presented with acute pancreatitis.
All the other LMNA nucleotide variations that we detected in these patients were silent polymorphisms either exonic 
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phy and accumulation of fat in the lower part of the body. We did not find any alteration in LMNA coding sequence in any of these patients. Furthermore, 5 of 10 congenital lipoatrophic patients born from consanguineous unions were heterozygous for several intragenic polymorphisms, suggesting that defects at the LMNA locus are not responsible for this rare autosomal recessive disease (7) .
The evaluation of the main clinical and biological characteristics of individuals bearing LMNA mutations revealed that the disease expressivity was variable, especially between men and women (Table 1 ). In women, limb and trunk lipoatrophy with muscular hypertrophy was generally present and associated with fat accumulation in face and neck, giving a cushingoid appearance. However, this classical phenotype was not universally evident, especially in lean patients, in whom lipoatrophic signs could be predominant. Signs of hyperandrogenism were generally present in affected women, albeit of varying severity. In men, the clinical diagnosis of FPLD was more problematic because of the absence of the characteristic lipodystrophy in most cases, as reported previously (8) . Insulin resistance and hypertriglyceridemia were also generally more severe in women. Three individuals, all lean women (DE1, K3, JM), presented with severe diabetes poorly controlled despite high dose insulin therapy (>100 U per day), whereas their affected male relatives had either a normal glucose tolerance (K5) or milder forms of diabetes, easily controlled by oral hypoglycemic agents (DE2 and 3). In the same way, six patients (all women) had striking hypertriglyceridemia that led to acute pancreatitis in two of them (G3 and K3).
In most cases, the lipodystrophy appeared progressively after puberty and was secondary to the first biological signs, either hyperinsulinemia or hypertriglyceridemia, when evaluated. Two prepubertal children, H13 and H15, were bearing the mutation without any phenotypic features of FPLD. At 22 years of age, subject DE4 still has a normal clinical and biological phenotype, suggesting either incomplete penetrance or a delayed form of the disease.
Because mutations in LMNA are also responsible for Emery-Dreifuss muscular dystrophy (EDMD) (9,10) and dilated cardiomyopathy and conduction-system disease (CMD1A) (11, 12) , we searched for clinical features of skele- Men  DE2  22  19  LA  D  +  -DE3  54  NO  D  --G1  46  NO  D  +  -H1  45  NO  IR  --H9  15  25  NO  ---H11  38  NO  ---H13  12  NO  ---H15  7  NO  ---K5  24  22  NO  -+  -P2  27  26.7  NO  ---P10  36  30  FPLD  NA  NA  - All patients bear an R482W heterozygous mutation in LMNA, except JM and PI, who carry an R482Q and an R584H heterozygous mutation, respectively. *Severe insulin resistance is defined by severe hyperinsulinemia (>140 pmol/l in the fasting state and/or >700 pmol/l 2 h after a 75-g oral glucose tolerance test) in the absence of diabetes. FPLD, lipoatrophy of limbs and trunk with fat accumulation in neck and face; LA, predominant lipoatrophy; NO, not obvious; NA, not available; +, present; -, absent.
tal or cardiac muscular dysfunction in our patients. With only one exception, FPLD patients had no history of muscular weakness and/or contractions. Most of them displayed a characteristic muscular hypertrophy with athletic appearance, whereas muscular atrophy is a typical feature of EDMD.
In patient H10, a proximal myopathy that did not fit the diagnostic criteria for EDMD (13) was noted. The level of serum creatine-kinase was found within the normal range in all the patients tested. Electrocardiography performed in eight patients did not reveal any rhythm or conduction abnormality. No history of cardiac rhythm disturbance or cases of sudden death in patients' relatives were reported. In FPLD, all of the previously reported mutations except one were clustered within exon 8, coding for a proximal C-terminal domain of lamin A/C, and concerned only three codons (465, 482, and 486) (2-5). In our patients, the LMNA mutation affected codon 482 in all of the cases but one, confirming that exon 8, and in particular codon 482, is indeed a mutational hot spot for FPLD. This is in contrast with what is seen in EDMD and CMD1A, in which most alterations reported to date are located either in the central rod dimerization or in the tail domain of lamin A/C, with only one reported mutation localized to exon 8 of the gene (I469T) (9) (10) (11) (12) .
Interestingly, we found in a typical FPLD patient a novel mutation located at codon 584, in the distal part of the coding sequence, within a highly conserved region of the C-terminal domain specific for the lamin A isoform. Recently, a R582H heterozygous substitution has been reported in FPLD, although in a less clinically pronounced form (4). It has been observed in vitro that the lamin A-specific C-terminal domain acts as a binding site for nuclear actin, with these two components being implicated in the organization of nuclear chromatin domains. Therefore, it is possible that these lamin A-specific mutations, through alterations in the nuclear lamina-chromatin relations, could modify the expression of adipose tissue-specific genes (5, 14) .
Molecular screening for LMNA mutations in FPLD may not be limited to the exon 8 of the gene. It is important to distinguish FPLD from other forms of lipodystrophies, especially acquired generalized lipoatrophy, in which clinical presentation could be very similar and to ensure the diagnosis in men, in whom the clinical and biochemical features may be less marked.
RESEARCH DESIGN AND METHODS
Patients. All patients and their families gave their informed consent for genetic studies, which were approved by an institutional review committee.
The biological and clinical characteristics of patients DE1 and K3 have been previously reported (15, 16) . Patients DE1 and 2 were also affected by familial benign hypercalcemia caused by a heterozygous mutation in the calciumsensing receptor gene (17) . Most patients with congenital and acquired generalized lipoatrophy have been previously presented (18, 19) . Genetic studies. Genomic DNA was obtained from peripheral white blood cells by standard procedures (20) . LMNA exons 1 to 12 and the surrounding intronic sequences were amplified by polymerase chain reaction (PCR) using primers and conditions previously described (3, 9) . After purification on Qiagen columns, the PCR products were directly sequenced using the ABI Dye terminator mix. Reactions were run on an ABI 377 sequencer and analyzed with Sequence Analysis 3.2 software (Perkin Elmer).
A rapid genotyping assay was used to screen for the mutations in exons 8 and 11 of LMNA. After amplification with specific primers (8F: 5Ј-CCAAGAG CCTGGGTGAGCCTC-3Ј, 8R: 5Ј-GACACTTACCCCAGCGCTCC-3Ј or 11F: 5Ј-TG GTCAGTCCCAGACTCGCC-3Ј, 11R: 5Ј-GCCTGCAGGATTTGGAAGA-3Ј), PCR products (15 µl) were digested with 10 U of the specific restriction enzymes (New England BioLabs, Beverly, MA). After a 3-h incubation at 37°C, the fragments were separated on a 3% agarose gel and visualized after staining with ethidium bromide. The C to T transition at codon 482 abolishes an MspI restriction site in the exon 8-PCR fragment of 229 bp, leading to a 183 bp additional DNA fragment (Fig. 1) . The G to A transition at codon 584 creates a unique Dra III restriction site in the exon 11-PCR product (360 bp), which generates two DNA fragments of 259 and 101 bp.
ACKNOWLEDGMENTS
This work was supported by grants from INSERM, Aide aux Jeunes Diabétiques, the British Diabetic Association (PhD studentship, D.J.L.), the British Heart Foundation (R.C.T.), and Programme Hospitalier de Recherche Clinique and Direction de la Recherche Clinique-Assistance Publique-Hôpitaux de Paris at the Clinical Investigation Center of Saint-Antoine University Hospital.
We thank the patients and their families for their collaboration; the physicians that have previously referred to us lipodystrophic patients; Drs. Pascale Benlian, Antoine Gancel, Caroline Lapouille, and Laurent Meyer for providing us with clinical and biological informations about their FPLD patients; Dr. Gisèle Bonne for the helpful advice about molecular analysis of LMNA; Drs Jon-Andoni Urtizberea and HenriMarc Bécane for medical information about EDMD patients; Dr. Dominique Récan and her colleagues for immortalization of lymphocytes; the Molecular Biology Laboratory of St. Antoine Hospital, Paris (directed by Prof E. Clauser) for LMNA sequencing; and Muriel Meier for her technical expertise and Betty Jacquin for her expert secretarial assistance.
